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Epstein-Barr virus (EBV) infects both B lymphocytes and squamous epithelial cells in vitro, but the cell
type(s) required to establish primary and persistent infection in vivo has not been definitively elucidated. The
aim of this study was to investigate a group of individuals who lack mature B lymphocytes due to the rare
heritable disorder X-linked agammaglobulinemia in order to determine the role of the B cell in the infection
process. The results show that none of these individuals harbored EBV in their blood or throat washings.
Furthermore, no EBV-specific memory cytotoxic T lymphocytes were found, suggesting that they had not
undergone infection in the past. In contrast, 50% of individuals were found to carry human herpesvirus 6,
showing that they are infectible by another lymphotropic herpesvirus. These results add weight to the theory
that B lymphocytes, and not oropharyngeal epithelial cells, may be required for primary infection with EBV.
Epstein-Barr virus (EBV) is a human herpesvirus carried by
more than 90% of the world adult population as a lifelong,
persistent infection (32). Primary infection usually occurs dur-
ing childhood when it is generally asymptomatic; however, if
primary infection is delayed until adolescence or early adult-
hood, infectious mononucleosis (IM) occurs in around 50% of
individuals (16).
EBV transmission is almost exclusively via the salivary route,
and virus can be recovered from throat washings of most se-
ropositive individuals and IM patients (11). It is thought that,
during primary infection, virus enters the body through initial
infection of the oropharyngeal epithelium and thus infects B
lymphocytes circulating through the lymphoid tissue at this site
and subsequently disseminates and establishes persistence in
the mature B-cell population (reviewed in reference 44). There
is convincing evidence to suggest that B lymphocytes are the
site of EBV persistence. For example, it has been shown in IM
patients and individuals suffering from herpes zoster that EBV
B-cell infection is maintained during acyclovir therapy, while
virus shedding into saliva is almost completely abrogated (56,
57). Similarly, persistent infection was entirely lost by obliter-
ation of B cells in an EBV-positive individual prior to bone
marrow transplant from an EBV-negative donor. The recipient
remained free from infection until more than 3 years posttrans-
plant and subsequently acquired an EBV strain different from
that of the original infection (14).
After primary infection, EBV can be detected in the periph-
eral blood of healthy seropositive individuals. Spontaneous
outgrowth of virus carrying B cells from peripheral blood gives
rise to B lymphoblastoid cell lines (LCLs) in culture (37) and
PCR analysis of peripheral blood cell DNA can detect viral
genomes. By these two methods, EBV-infected circulating B
lymphocytes are detected at a frequency of approximately 1 to
60 per million (24, 31).
In healthy seropositive individuals, EBV-specific cytotoxic T
lymphocytes (CTLs) to a wide range of EBV epitopes are
readily detectable in the circulation (reviewed in reference 45).
It is assumed that, in order to persist for the lifetime of the
host, the virus must evade immune recognition by establishing
a form of latent infection with minimal expression of viral
proteins (reviewed in reference 54). However, for EBV to be
successfully transmitted, it must effect egress from the host.
Thus, a lytic infection with the production of cell-free virus
particles must occur at or near an epithelial surface. This is
thought to occur via a reversal of the route of viral entry,
involving the reinfection of epithelial cells by virus carrying B
lymphocytes circulating through the lymphoid tissue of the
oropharynx. Virus replication is postulated to occur in the
infected epithelial cells, with infectious virus particles released
into the saliva, and, from this site of production, the virus
spreads to other individuals (reviewed in reference 44). The
mechanism of passage of virus from lymphocytes to epithelial
cells is unclear because until recently, there was little evidence
of lytic replication in B cells in vivo, although productive in-
fection can be induced in LCLs in vitro (reviewed in reference
44). Support for this route of infection and transmission came
from experiments showing that the virus can infect human
cervical epithelial cells in vitro (51) and an in vivo demonstra-
tion that exfoliated oropharyngeal cells of IM patients, thought
to be epithelial, contained replicating virus (25, 50).
Epithelial cell infection is also seen in vivo in the cells of the
benign, EBV-associated lesion, oral hairy leukoplakia (OHL).
Since this lesion mainly occurs in immunocompromised human
immunodeficiency virus-infected individuals (reviewed in ref-
erence 15), where reactivation of persistent virus infections is
common, it has been considered to represent an amplification
of normal events. However, studies on OHL showing that
infected epithelial cells are situated in the superficial layers of
the epithelium and that no viral DNA or protein expression is
detectable in the basal layer have suggested that this lesion is
perhaps caused by repeated infection of mature epithelial cells
by saliva-borne virus (36, 49; reviewed in reference 15).
Extensive research on naso- and oropharyngeal tissues from
both IM and healthy donors has failed to identify any infected
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epithelial cells, although both latently (19, 34, 35) and lytically
(33, 53) infected B lymphocytes are seen in the underlying
lymphoid tissues, infiltrating the epithelial layers and also on
the surface of the tonsillar epithelium (2). These findings
prompted some workers to question the infection of epithelial
cells in vivo (34, 53) and to suggest that the whole of the EBV
life cycle, including entry to and egress from the host, can be
accomplished by B-cell infection alone (19, 33, 54). This had
been thought unlikely as there was little in vivo evidence of
productive infection of B lymphocytes. However, it has re-
cently been shown that B lymphocytes are capable of support-
ing lytic EBV replication in vivo both in peripheral blood (12,
41) and in those lymphocytes infiltrating the oropharynx (2, 33,
53). Thus, it no longer seems impossible that the B lymphocyte
is the cell type exclusively exploited by EBV for primary and
persistent infection of humans.
In light of the ongoing controversy regarding the role of
oropharyngeal epithelial cells and B lymphocytes in EBV bi-
ology, our aim was to reassess the situation using a model
where infection of B lymphocytes cannot occur. We have
therefore looked for evidence of EBV infection in individuals
with X-linked (Bruton’s) agammaglobulinemia (XLA). These
individuals possess inherited mutations in the gene encoding
Bruton tyrosine kinase (Btk). Defects in this cytoplasmic ty-
rosine kinase, involved in cell signalling, result in a block to
B-cell development and consequently a lack of mature circu-
lating B lymphocytes (reviewed in reference 38). The absence
of B lymphocytes results in agammaglobulinemia. XLA pa-
tients thus have increased susceptibility to opportunistic bac-
terial infections, although their T-cell immunity and resistance
to viral infections is not affected (reviewed in reference 38).
We have looked for evidence of EBV infection in these
“human B-cell knockouts” to determine the fate of the virus in
the absence of B lymphocytes, but where oropharyngeal epi-
thelium is intact.
MATERIALS AND METHODS
XLA patients. Whole-blood and throat washing samples were collected from
individuals suffering from XLA, a rare primary immunodeficiency. A group of six
male patients were studied, drawn from the south of England, who attended a
clinic at the John Radcliffe Hospital, Oxford, United Kingdom, every 2 to 4
months. All had increased susceptibility to recurrent bacterial infections present-
ing in childhood between 2 and 7 years of age. Each received immunoglobulin
replacement therapy from the time of their original diagnosis. Four patients first
received intramuscular immunoglobulin which gave low serum immunoglobulin
levels of 2 to 4 g/liter and were switched to intravenous therapy (serum immu-
noglobulin levels of 6 to 10 g/liter) at 11 to 39 years of age. All patients now
receive intravenous infusions of pooled donor immunoglobulin two or three
times a week. These infusions are generally self-administered at home. The ages
and samples obtained from each patient are shown in Table 1.
B- and T-cell immunophenotyping. Peripheral blood T-cell (CD31, CD41/
CD81) and B-cell (CD19,201) numbers were enumerated by dual-color flow
cytometry using a Becton-Dickinson (Oxford, United Kingdom) FACS. Mono-
clonal antibodies used were fluorescein isothiocyanate anti-CD3, phycoerythrin-
labelled anti-CD4, anti-CD8, anti-CD19, and anti-CD20. All were obtained from
Becton-Dickinson, and were used at standard dilutions according to the manu-
facturer’s instructions. EDTA-anticoagulated samples were analyzed and stained
within 3 h of collection.
Indirect immunofluorescence staining. Serological testing for immunoglobulin
G (IgG) antibodies to EBV viral capsid antigen (VCA) was performed on four
XLA patients and all healthy donors by routine methods (17). XLA patient sera
were shown to contain infused antibodies to VCA at titers of no significant
difference to those found in healthy seropositive donors (P . 0.2).
All XLA patients’ throat washing supernatants were also tested by the same
method for the presence of anti-VCA IgG.
Maintenance of cell lines. Control LCLs, B95-8 (American Type Culture
Collection [ATCC], Rockville Md.) (29) and MLA-144 (ATCC) cell lines were
maintained in standard culture medium containing RPMI 1640 supplemented
with 2 mM L-glutamine, 100 IU of penicillin per ml, 100 mg of streptomycin per
ml and 10% heat-inactivated fetal calf serum (FCS) (Gibco BRL, Middlesex,
United Kingdom).
Isolation of PBMC for tissue culture and PCR. Whole blood that had been
treated with heparin was diluted 1:1 in RPMI 1640 containing 2% FCS (2%
FCS/RPMI 1640) and layered onto an equal volume of Ficoll-Hypaque (Phar-
macia Biotech, Uppsala, Sweden). Following centrifugation at 840 3 g for 15
min, peripheral blood mononuclear cells (PBMC) were harvested from the
plasma-Ficoll interface. Cells for tissue culture were washed twice in 2% FCS/
RPMI 1640, counted, and either used immediately or suspended in 25% FCS/
RPMI 1640 containing 10% dimethyl sulfoxide, frozen at 270°C and subse-
quently stored in liquid nitrogen until use. PBMC for PCR analysis were washed
twice in phosphate-buffered saline and either used immediately for DNA extrac-
tion or quick-frozen and stored at 270°C for future use.
E-rosetting. T-cell depletion of PBMC samples was achieved as previously
described (23) by rosetting with 2-aminoethylisothiouronium bromide-treated
sheep erythrocytes followed by centrifugation over a Ficoll-Hypaque gradient
allowing separation of T cells (E1) from the residual mononuclear cell popula-
tion. The B-cell-enriched fraction (E2) were harvested from the Ficoll-medium
interface, washed in 2% FCS/RPMI 1640 and cultured immediately.
Generation of LCLs by infection of E2 cells with EBV. Concentrated prepa-
rations of the EBV strain B95-8 were prepared as described previously (23) and
used to infect E2 cells from all XLA patients and six healthy donors. Up to 2 3
107 E2 cells were incubated with virus preparation diluted 1:10 in 1 ml of
standard culture medium for 1 h at 37°C and 5% CO2. Cells were then suspended
at 106 per ml in standard culture medium and plated out at 2 ml per well in
24-well plates. Cultures were incubated at 37°C and 5% CO2 and maintained by
replacing half the volume of medium each week. Cells were monitored regularly
for signs of immortalization until outgrowth occurred or cell viability was 0% (as
determined by trypan blue staining) (1 to 6 weeks).
Spontaneous outgrowth assays. Between 5 3 105 and 2 3 107 E2 cells were
plated at 106 per ml in standard culture medium in 96-well U-bottom plates at
200 ml per well. These cells were then incubated at 37°C and 5% CO2 and
monitored regularly for signs of immortalization. Cultures were maintained by
replacing half the volume of medium each week until either outgrowth occurred,
or cell viability was 0% as determined by trypan blue staining (2 to 9 weeks).
Immunostaining. LCLs obtained by either in vitro immortalization or spon-
taneous outgrowth were routinely screened for presence of viral nuclear antigens
(EBNAs) by standard anticomplement immunofluorescence methods (42).
Preparation of throat washing specimens. Throat washings were collected in
10-ml aliquots of isotonic (0.9%) saline. Samples were centrifuged at 600 3 g for
10 min in order to separate cellular material from supernatant. Cellular material
was quick-frozen and stored at 270°C until use or immediately used for DNA
extraction as described blow. Supernatants were concentrated 100 times by
ultracentrifugation at 25,000 3 g for 2 h at 4°C using a Beckman L8-80 ultra-
centrifuge and a type 50 rotor (Beckman Instruments, Palo Alto, Calif.). Control
tubes containing isotonic saline only were included in every centrifuge run to
ensure that there was no contamination of samples by extraneous EBV DNA.
The pellet was resuspended in 40 ml of sterile distilled water and incubated at
37°C for 1 h with 100 mg of proteinase K (Promega Corporation, Southampton,
United Kingdom) per ml. The enzyme was then inactivated at 100°C for 10 min.
Extraction of DNA for PCR. DNA was extracted from fresh or frozen PBMC,
throat washing cell pellets, or control cell line samples by using the Easy-DNA kit
according to the manufacturer’s instructions (Invitrogen, BV Leek, The Neth-
erlands). DNA was dissolved in sterile distilled water, and the total DNA yield
was established by spectrophotometry (GeneQuant II; Pharmacia Biotech). One
microgram of DNA was taken to represent the yield from 1.5 3 105 cells based
on estimates that the human genome is 3 3 109 bp long and that the average
molecular mass of a nucleotide base is 330 Da.
Throat washing cell pellet DNA was also extracted using the Invitrogen Easy-
DNA kit, but DNA was resuspended in a standard 50-ml volume of sterile
distilled water and the total DNA yield was not established.
EBV W-repeat PCR. The EBV W-repeat PCR detects the BamHI-W-repeat
sequences of the EBV genome. The primers amplify a 298-bp fragment of the W
repeats. 59 primer; 59-CTTTAGAGGCGAATGGGCGC-39 (positions 14069 to
14088 inclusive). 39 primer; 59-AGGACCACTTTATACCAGGG-39 (positions
14366 to 14347 inclusive). Primer and probe coordinates for EBV were based on
TABLE 1. XLA patient ages and summary of samples obtained
from each patient over 18 months
XLA patient Age
a
(yr)
Amt (ml) of
whole blood
No. of throat washing
samples
Cell pellet Supernatant
XLA1 13 25, 40 3 2
XLA2 34 35, 16 2 2
XLA3 23 25, 23, 10 3 3
XLA4 22 25, 40, 7.5 2 3
XLA5 42 35, 25, 7.5 3 2
XLA6 10 7.5, 8, 35, 20, 9 3 1
a Age at time of collection of the first sample.
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the published prototype DNA sequence (3) (available from the GenBank nu-
cleotide sequence database under accession number V01555).
PCR was performed in a final volume of 100 ml with either 1 mg of PBMC
DNA, 10 ml of throat washing cell pellet DNA solution, or 10 ml of concentrated
throat washing supernatant per reaction. LCL or B95-8 DNA (1 mg) was in-
cluded as a positive control, and 1 mg of PBMC DNA from a seronegative donor
was included as a negative control. Reagent-only reactions were also included to
control for DNA contamination.
Samples were denatured at 95°C prior to PCR cycling. The amplification
mixture contained the following: 13 PCR buffer (50 mM KCl, 10 mM Tris-HCl
[pH 9.0] and 0.1% Triton X-100) (Promega) plus 1.5 mM MgCl2 (Promega), 0.2
mM each of the four deoxynucleoside triphosphates (Pharmacia), 1 mM (each)
primer (Oswel DNA Service, University of Southampton, Southampton, United
Kingdom), 2.5 U (0.5 ml) of Taq polymerase (Promega) per reaction. Reactions
were overlaid with mineral oil (Sigma Chemical, Poole, Dorset, United King-
dom). The reaction mixtures were incubated in an Omnigene thermal cycler
(Hybaid, Middlesex, United Kingdom) under the following cycling conditions: 35
cycles of PCR, with 1 cycle consisting of 1 min at 94°C, 2 min at 45°C, and 2 min
at 72°C.
To determine whether samples contained DNA suitable for PCR amplification
and to test for false negatives, all samples were also screened for the human
b-globin gene (48).
In order to determine the sensitivity of the W-repeat PCR, a plasmid, pBSW,
containing a single copy of a W-repeat sequence, was diluted into human PBMC
DNA from a seronegative donor. Having established accurate concentrations of
a plasmid solution in sterile distilled water by spectrophotometry, the copy
number per microliter was calculated based on the fact that pBSW is 6.03 3 103
bp long and the estimate that the average mass of a nucleotide base is 330 Da.
Serial dilutions were made of pBSW and between 0 and 106 copies in a back-
ground of DNA from 5 3 105 PBMC from a seronegative donor were used in
W-repeat PCRs. The results of one such experiment are shown in Fig. 1A. The
W-repeat PCR was consistently found to be capable of detecting one copy of the
W fragment in a background of DNA from 5 3 105 cells.
HHV-6 PCR. DNA from PBMC was screened for human herpesvirus 6
(HHV-6) by PCR (13). In our hands, this had previously been shown capable of
detecting HHV-6 in concentrated sera obtained from healthy donors and heart-
lung transplant recipients (unpublished data). Briefly, a 233-bp product is gen-
erated using the primer set 59-AAGCTTGCACAATGCCAAAAAACAG and
39-CTAATCCCCAGAGCCGTATGAGCTC in a 100-ml reaction mixture using
the same reaction conditions used in the EBV W-repeat PCR and the following
cycling conditions: 40 cycles, with 1 cycle consisting of 1 min at 94°C, 1 min at
65°C, and 2 min at 72°C. Supernatant from the T-cell line J-jhan infected with
HHV-6 was used as a positive control. DNA extracted from B95-8 was used as
a negative control. Reagent-only reactions were also included to control for
DNA contamination.
Gel electrophoresis and Southern blotting. PCR products were separated by
gel electrophoresis using 2.5% agarose (type II-A; Sigma) containing 1 mg of
ethidium bromide (Sigma) per ml. The molecular weight marker fX174 digested
with HinfI (Promega) end labelled with [g-32P]dATP (Amersham International,
Little Chalfont, Buckinghamshire, United Kingdom) was always included. Fol-
lowing electrophoresis, gels were transferred and UV cross-linked to positively
charged nylon membranes (Hybond-N1; Amersham) according to the manufac-
turer’s instructions for Southern blotting.
Blots were then prehybridized at 42°C for 2 h in a solution containing 50%
deionized formamide, 53 Denhardt’s solution, 53 SSC (13 SSC is 0.15 M NaCl
plus 0.015M sodium citrate), 0.5% sodium dodecyl sulfate (SDS), and 100 mg of
denatured sheared salmon sperm DNA (CP Labs, Bishops Stortford, Hertford-
shire, United Kingdom) per ml. DNA hybridization oligonucleotide probes used
were as follows: for EBV W-repeat PCR products, 59-TGACTTCACCAAAGG
TCAGG-39 (14227 to 14246 inclusive). For HHV-6 PCR products, 59-AACTG
TCTGACTGGCAAAAACTTTT-39. (Oswel).
Probes were labelled with [g-32P]dATP (Amersham) using T4 polynucleotide
kinase (Promega) by incubating 5 pmol of probe and 1.85 MBq of [g-32P]dATP
for 30 min at 37°C with 10 U of enzyme in a buffer containing 70 mM Tris-HCl
(pH 7.6), 10 mM MgCl2, and 5 mM dithiothreitol (Promega). Labelled probes
were purified by fractionation on a Sephadex column (NICK columns; Pharma-
cia) according to the manufacturer’s instructions. Labelled probes were then
applied to the prehybridized membranes with the addition of a further 100 mg of
denatured sheared salmon sperm DNA per ml and left to hybridize at 42°C for
at least 12 h. Hybridized blots were washed in 23 SSC–0.1% SDS and 0.23
SSC–0.1% SDS and then exposed to Hyperfilm-MP (Amersham) for 7 days at
270°C.
HLA genotyping. DNA was extracted from EDTA-anticoagulated peripheral
blood by a rapid salting-out method (30). Genotyping of the HLA class I A and
B loci was performed by using PCR and sequence-specific primers as previously
described (6).
Bulk CTL reactivation and limiting dilution analysis (LDA). On occasion,
cells were stored frozen prior to these assays. Previous experience of the authors
(S.R.B., R.K., and D.J.M.) and others (52) has shown that these cells respond
normally after thawing.
Responder cells were either fresh PBMC (healthy donors), thawed PBMC,
and/or T-cell-enriched E1 cells (XLA patients 1 and 2) (Table 2).
Stimulator cells were either autologous fresh PBMC (healthy donors), thawed
PBMC, and/or T-cell-enriched E1 cells (XLA patients 1 and 2) (Table 2).
Stimulator cell pellets were resuspended in 100-mg/ml solutions of synthetic
peptide diluted in RPMI 1640 and incubated at 37°C and 5% CO2 for 45 min.
Peptide-treated cells were then washed twice in RPMI 1640. Peptides were
purchased from Chiron Mimotopes (Melbourne, Australia).
For bulk CTL reactivation, responder cells were cultured with autologous
peptide-treated stimulator cells at a ratio of 3:1 (1.5 3 106 to 0.5 3 106) at 106
per ml in standard culture medium, plated out at 2 ml per well in 24-well plates,
and incubated at 37°C and 5% CO2. After 7 days, responders were restimulated
with a further 0.5 3 106 autologous peptide-treated stimulator cells. In one case,
105 gamma-irradiated (80 Gy) allogeneic HLA-matched LCL cells were used
(Table 2). Cultures were expanded by addition of more standard culture medium
when required. Cytotoxicity assay by chromium release was performed on day 10
or 12 of culture.
For LDA, responder cells were plated out in U-bottom 96-well plates at the
following cell numbers per well in 24 replicates: 50 3 103, 25 3 103, 12.5 3 103,
and 6.25 3 103. Autologous peptide-treated stimulator cells, prepared as de-
scribed for bulk CTL reactivation, were gamma irradiated (20 Gy) and cultured
with responders at 5 3 104 per well. In one case, 104 allogeneic gamma-irradiated
(20 Gy) BL30/EBO-pLPP-Sig-FLRG cells were used as stimulators. The BL30/
EBO-pLPP-Sig-FLRG line is a Burkitt’s lymphoma (BL) cell line transfected
with an expression plasmid (EBO-pLPP-Sig-FLRG) encoding an endoplasmic
reticulum translocation signal followed by the epitope FLRGRAYGL (EBNA-
3A). This cell line has been shown previously to be a very efficient stimulator of
memory T cells specific for FLRGRAYGL from healthy seropositives (20). The
final culture volume was 100 ml in standard culture medium. On days 3 and 7,
cultures were fed with 50 and 100 ml, respectively, of medium containing 10%
FCS/RPMI 1640 supplemented with 2 mM L-glutamine, 100 IU of penicillin per
ml, 100 mg of streptomycin per ml, 30% MLA-144 (ATCC) conditioned medium
(filtered and heat inactivated), and 20 U of recombinant interleukin-2 per ml (47,
55) (referred to as T-cell medium). Where necessary, 100 ml of T-cell medium
was replaced on day 10 or 11. Cytotoxicity assay by chromium release was
performed between days 10 and 14.
TABLE 2. Summary of CTL experiments performeda,c
Patient or donorb
(HLA type)
Responders:stimulators
Target cell type
Bulk CTL reactivation LDA
XLA1 (HLA-B8) E1:E1 restimulated with allogenic HLA-
matched LCL
E1:BL30/EBO-pLPP-Sig-FLRG
(allogeneic)
Allogeneic HLA-matched
PHA blasts
XLA2 (HLA-B44) E1:E1 and PBMC:PBMC both
restimulated with PBMC
PBMC:PBMC PHA blasts
XLA3 (HLA-B44) PBMC:PBMC restimulated with PBMC ND PHA blasts
XLA4 (HLA-B7) ND PBMC:PBMC PHA blasts
XLA5 (HLA-B44) PBMC:PBMC restimulated with PBMC ND PHA blasts
XLA6 (HLA-B44) ND E1:PBMC PHA blasts
NHD 19 (HLA-B8) PBMC:PBMC restimulated with allogenic
HLA-matched LCL
PBMC:BL30/EBO-pLPP-Sig-FLRG
(allogeneic)
Allogenic HLA matched
PHA blasts.
a Responder, stimulator, and target cell types for bulk CTL reactivations and LDA.
b XLA, XLA patient; NHD, normal healthy donor.
c All cells autologous unless otherwise stated. E1, T-cell-enriched PBMC. ND, not done.
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Generation of PHA blasts. Phytohemagglutinin (PHA) blasts were generated
from fresh PBMC (healthy donors), thawed PBMC or E1 (XLA patients) by
culturing cells in standard culture medium containing 20 mg of PHA (CSL,
Melbourne, Australia) per ml at 5 3 105 per ml. On day 3, cells were harvested,
washed in RPMI 1640, and resuspended in T-cell medium at the same concen-
tration. Cultures were expanded by doubling the volume of medium twice
weekly.
Chromium release assay. Cytotoxic activity of responder cells was assessed by
standard chromium release assay. Target cells were autologous PHA blasts or
allogeneic HLA-matched PHA blasts treated with peptide as described above
(Table 2). Both peptide-treated and untreated targets were labelled with 3.7
MBq of 51Cr (sodium chromate; Amersham) at 37°C and 5% CO2 for 90 min and
washed twice in standard culture medium.
Bulk reactivation CTLs were harvested, their viability was assessed by trypan
blue staining, and the CTLs were applied to targets at effector-to-target ratio of
20:1. Either two or three replicates were performed for each target cell type.
LDA effectors (50 ml) from each well were applied to 104 cells of each target
cell type.
Spontaneous release (targets plus standard culture medium only) and maxi-
mum release (targets plus medium containing 0.1% SDS) controls were included
for each target cell type. Effectors and targets were incubated for 5 h at 37°C and
5% CO2, and supernatants were then assessed for 51Cr levels by beta-scintillation
counter (Topcount Microplate; Packard Instrument Co., Meriden, Conn.). The
release of 51Cr was used to calculate the specific lysis of targets by effectors.
Statistical analyses. The two-tailed Fisher exact x2 test and Student’s t test
were used.
RESULTS
EBV cannot be detected in the throat washings of XLA
patients. In order to establish whether XLA patients were
harboring EBV in the oropharynx, throat washing samples
which had been separated into cell pellet and supernatant
components were screened for EBV DNA using primers di-
rected against the BamHI-W-repeat sequence. Cell pellet
DNA was extracted prior to screening. Supernatants were con-
centrated by ultracentrifugation. Each ultracentrifugation run
included a saline control in order to ensure that there was no
potential contamination of samples by extraneous EBV DNA
during this step; these samples always tested negative for EBV
by PCR. Figure 1A shows the results obtained from an exper-
iment carried out to assess the sensitivity of the PCR. The
technique could consistently detect one copy of target DNA in
a background of 5 3 105 EBV-negative cells.
No EBV-positive throat washing samples were found for any
XLA patient. This is in contrast with the 14 of 20 positive
samples obtained from 10 healthy seropositive donors (Table
3). In total, none of the six XLA patients compared to 8 of 10
healthy seropositive donors were found to have EBV DNA in
their throat washing samples (P , 0.01). Figure 1B shows an
example of positive PCR results obtained with throat washing
samples from healthy seropositive donors.
XLA patients have normal T-cell counts, but no B cells
infectible by EBV in the peripheral blood. Flow cytometric
analysis performed on PBMC obtained from each patient con-
firmed that they had no peripheral blood B lymphocytes, dem-
onstrated by CD19 and CD20 staining (Table 4). Analysis for
CD3, CD4, and CD8 however, showed that the XLA patients
had T-lymphocyte populations within normal ranges (Table 4).
In addition, whereas EBV infection of T-cell-depleted
PBMC gave rise to LCLs in 100% (six of six) healthy donors,
no immortalized cell lines were obtained from any of the XLA
patients, despite several attempts (P , 0.01) (Table 5). These
results confirm that the XLA patients investigated in this study
had no EBV-infectible cells in their peripheral blood.
XLA patients have no EBV in their peripheral blood. The
presence of EBV in the peripheral blood of the XLA patients
and healthy donors was assessed by both culture of T-cell-
depleted lymphocytes (E2) (spontaneous outgrowth assay)
and PCR analysis of PBMC DNA.
(i) Spontaneous outgrowth assay. Between 5 3 105 and 2 3
107 E2 lymphocytes obtained from PBMC were cultured at
106 per ml for between 2 and 9 weeks until cell viability was 0%
or spontaneous outgrowth of an LCL occurred. No LCLs were
generated from XLA patients by this method. This is in con-
trast to the results obtained with healthy seropositive donors,
where 3 of 11 donors produced a spontaneous LCL (Table 5).
Since the spontaneous outgrowth assay depends on the pres-
ence of B cells in the culture to rescue virus particles released
by infected cells (43), it is possible that virus was carried and
released by non-B cells in the XLA culture and not detected in
FIG. 1. EBV DNA detection by PCR in throat washings and PBMC of
healthy EBV seropositive donors. (A) W-repeat PCR sensitivity. PCR products
obtained from a dilution of plasmid pBSW in a background of DNA from 5 3
105 PBMC from seronegative donor NHD14 were analyzed by Southern blotting
and hybridization. Lanes 1 and 2, PCR reagent controls containing water instead
of template DNA; lanes 3 to 11, results obtained from PCR on plasmid dilutions
ranging from 0 to 106 starting copies per PCR (pBSW template copy number per
PCR is indicated below each lane); lane 12, product from 0.1 mg of DNA
obtained from the EBV-positive cell line B95-8. (B) PCR products obtained
from concentrated throat washing supernatants of healthy donors. Lanes 1 and
2, PCR mix controls containing water instead of template DNA; lane 3, product
obtained from 1 mg of PBMC DNA from seronegative donor NHD14; lanes 4
and 5, products from concentrated throat washing samples from seropositive
donor NHD3; lanes 6 to 8, products from concentrated throat washing samples
from seropositive donor NHD13; lanes 9 to 11, reactions using saline control
included in the ultracentrifugation step as described in Materials and Methods;
lane 12, PCR mix control containing water instead of template DNA; lane 13,
product from 1 mg of EBV LCL DNA. (C) PCR screening of healthy seropositive
donor PBMC DNA. Lanes 1 and 2, PCR mix controls containing water instead
of template DNA; lane 3, reaction using 1 mg of PBMC DNA from seronegative
donor NHD14; lanes 4 to 11, PCR products from eight replicate reactions, each
done on 1 mg of DNA obtained from PBMC of seropositive donor NHD6; lane
12, PCR mix control containing water instead of template DNA. Lane 13,
product from 1 mg of DNA obtained from an EBV LCL.
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this assay. In addition, the method is not highly sensitive and
gave positive results in only a small number of healthy EBV-
infected donors (27%). PCR screening was therefore also em-
ployed.
(ii) PCR analysis. BamHI-W PCR was performed on DNA
extracted from approximately 1.5 3 105 PBMC per reaction (1
mg). Replicate reactions were undertaken to utilize the maxi-
mum DNA available (from between 1.5 3 106 and 107 cells
[Table 3]). By this method, all six XLA patients were negative
for EBV in their PBMC DNA (Table 3). This is compared to
detection of EBV in four of eight healthy seropositive donors
(Table 3). Figure 1C shows an example of the positive PCR
result found for seropositive donor NHD6. The seronegative
donor tested was negative for EBV by PCR (Table 3). Com-
parison of the total numbers of PCRs gives no (of 282) positive
results for XLA patients and 35 (of 336) positives (P , 0.01)
(Table 3).
XLA patients have no memory CTLs specific for EBV. Pe-
ripheral blood cell samples from each patient were assessed by
bulk reactivation and/or LDA for the presence of CTLs spe-
cific for EBV. Generally, responder cells (PBMC or T-cell-
enriched [E1] fractions) (Table 2) from each patient were
cultured in the presence of stimulator cells presenting EBV
synthetic peptides known to be presented by the HLA type of
each patient and that had been shown to stimulate an EBV-
specific CTL response from healthy seropositive donor PBMC
in vitro (Table 6).
Stimulator cells used were either E1 or PBMC treated with
synthetic peptides or alternatively the BL30/EBO-pLPP-Sig-
FLRG cell line presenting the epitope FLRGRAYGL
(EBNA-3A) (20) (Table 2). Stimulated cells (effectors) were
applied to peptide-treated autologous or allogeneic HLA-
matched PHA blasts, and specific lysis of these target cells was
assessed by chromium release cytotoxicity assay (Table 2).
Figure 2 shows that, for all XLA patients assessed by bulk
CTL reactivation, the percentage of specific lysis of peptide-
treated target cells was clearly not significantly different from
background killing (shown by the lysis of untreated targets).
This result indicates that XLA patients have no memory T cells
to these EBV epitopes (P 5 0.5). Bulk CTL reactivated from
healthy seropositive donors produced specific lysis levels
TABLE 3. Results obtained from PCR screening of throat washing samples and PBMC DNA from XLA patients and healthy donors
Patient or donora No. of PBMC screened (no. of reactions)b PBMC screening resultc
Throat washing samples screened
(no. positive/total no.)b
Cell pellet Supernatant
XLA1 1.0 3 107 (67) 2 0/3 0/2
XLA2 1.5 3 106 (10) 2 0/2 0/2
XLA3 4.0 3 106 (27)4.5 3 105 (30) 2 0/3 0/3
XLA4 3.1 3 106 (21)1.2 3 106 (8) 2 0/2 0/3
XLA5 5.4 3 106 (36)2.7 3 106 (18) 2 0/3 0/2
XLA6 1.0 3 107 (67) 2 0/3 0/1
NHD1 6.3 3 106 (42) 1 ND ND
NHD2 6.3 3 106 (42) 2 1/1 1/1
NHD3 ND ND 0/1 1/1
NHD4 6.3 3 106 (42) 2 1/1 0/1
NHD5 6.3 3 106 (42) 2 ND ND
NHD6 6.3 3 106 (42) 1 1/1 1/1
NHD7 6.3 3 106 (42) 1 0/1 0/1
NHD8 ND ND 2/2 1/1
NHD9 ND ND 0/1 1/1
NHD10 ND ND 1/1 1/1
NHD11 6.3 3 106 (42) 1 ND ND
NHD12 6.3 3 106 (42) 2 ND 0/1
NHD13 ND ND 1/1 1/1
NHD14 (seronegative) 6.3 3 106 (42) 2 ND ND
a XLA, XLA patient; NHD, normal healthy donor.
b ND, not done.
c 2, negative result; 1, positive result; ND, not done.
TABLE 4. FACS analysis of PBMC from XLA patients
XLA patient
Cell count (% of total PBMC)
CD31 CD41 CD81 CD191 CD201
XLA1 88 61 26 0 0
XLA2 83 59 23 0 0
XLA3 90 60 29 0 0
XLA4 89 65 24 0 0
XLA5 72 40 30 0 0
XLA6 92 48 44 0 0
TABLE 5. Results obtained from immortalization and spontaneous
outgrowth assays performed on XLA patients and healthy donors
Patient or donora
Resultb of assay
Immortalization Spontaneousoutgrowth
XLA1 2 2
XLA2 2 2
XLA3 2 2
XLA4 2 2
XLA5 2 2
XLA6 2 2
NHD2 1 2
NHD5 1 1
NHD6 1 1
NHD8 1 2
NHD11 1 1
NHD21c 1 ND
NHD1, -3, -4, -7, -9, and -10 ND 2
a XLA, XLA patient; NHD, normal healthy donor.
b 2, negative result; 1, positive result; ND, not done.
c Seronegative.
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against peptide-treated targets which were significantly (P ,
0.01) greater than background killing, indicating that a strong
CTL response had been stimulated (Fig. 2).
LDA is a highly sensitive method for the screening of mem-
ory CTLs. Figure 3 shows the results obtained from the LDA
experiments. The proportion of wells containing EBV-specific
CTLs for each original dilution of cells (50,000 to 6,250) was
0% in every case for XLA patients and healthy seronegative
donors. However, for healthy seropositive donors, the propor-
tion of wells containing EBV-specific CTLs for each original
dilution of cells ranged from 54 to 8% for donor 17 and 100 to
62.5% for donors 18 and 19 (Fig. 3). Thus, XLA patients show
no evidence of an EBV-specific memory CTL response in the
peripheral circulation.
XLA patients have no mucosal immunity to EBV. In order to
establish the role of infused donor IgG in the passive immu-
nization of XLA patients against EBV infection, throat wash-
ing samples from each patient were assessed for the presence
of anti-EB VCA IgG. Since the infusions are known to contain
only trace amounts of IgA, this was not screened for. Undi-
luted throat washing supernatants were tested by using an
indirect immunofluorescence assay and were shown to contain
no detectable anti-VCA IgG.
XLA patients are infectible by the lymphotropic HHV-6.
PCR analysis for HHV-6 was performed on DNA extracted
from 106 PBMC for each XLA patient and five healthy donors
of unknown HHV-6 serological status in order to screen for
the presence of another lymphotropic herpesvirus. Three of six
patients and two of five healthy donors were PCR positive for
HHV-6. These incidences concur with data published by other
workers using PCR for detection of HHV-6 in normal donors
(13). There is no significant difference between the results
obtained from XLA patients and healthy donors (P 5 1).
Figure 4A and B show the PCR results obtained from both
patients and donors.
DISCUSSION
In vitro EBV infection of squamous epithelial cells was re-
ported in the early 1980s (51), and following this, EBV DNA
was demonstrated in exfoliated oropharyngeal epithelial cells
from patients with IM (50). These observations led to a uni-
versally accepted model of EBV biology in which productive
infection of oropharyngeal epithelial cells played a key role in
the primary infection and transmission of EBV and in the
infection of B lymphocytes. It was also suggested that the
lifelong persistence of EBV may result from infection of basal
epithelium of the oropharynx with cellular maturation-linked
viral gene expression culminating in full productive infection in
the mature surface cells (1) in a fashion analogous to papillo-
mavirus infection of the epidermis (28). However, experimen-
tal evidence to support this theory is scarce, and convincing
data has accumulated to suggest that the virus persists in the
host by establishing a latent infection in B lymphocytes. Re-
cently, the role of epithelial cells in primary infection has also
been challenged by several workers using in situ hybridization,
immunohistology, and PCR techniques to detect EBV RNA,
proteins, and DNA in oropharyngeal cells (2, 19, 33–35, 53).
These experiments detect latent and lytic infection in intraepi-
thelial B cells but no epithelial cell infection. Since it could be
argued that these essentially negative data result from the
insensitivity of the techniques used to detect EBV and/or the
rarity of the infected cells in the epithelium, we have used an
entirely different approach to investigate the cell type(s) re-
quired for EBV infection and transmission.
Six XLA patients with a rare genetic mutation of the cyto-
plasmic tyrosine kinase gene, which results in a complete ab-
sence of mature circulating B cells, were studied. Although
immature B cells may be present in the bone marrow of XLA
patients (38), by flow cytometry we found no CD19- or CD20-
positive cells in the peripheral blood samples of our cohort,
indicating that no mature circulating B cells were present.
Similarly, we were unable to generate LCLs from their periph-
eral blood T-lymphocyte depleted cells by in vitro infection
with EBV preparations known to produce LCLs from 100% of
peripheral blood B-cell samples from healthy donors. These
results indicate that the patients studied had no circulating B
cells capable of supporting EBV infection.
Since XLA patients have no antibody-producing cells and
are regularly infused with pooled immunoglobulin prepara-
tions from large numbers of donors, we could not use conven-
tional serological testing to determine past exposure to EBV.
However, using the tissue culture method of spontaneous out-
growth of LCL, we showed consistently negative results from
all XLA patient samples which were in sharp contrast to those
found with healthy seropositive donors where 27% of donors’
E2 cells grew into an LCL. A sensitive PCR technique which
regularly detects one copy of target EBV DNA in a back-
ground of DNA from half a million EBV-negative cells was
also used to screen for virus in patient and healthy donor
peripheral blood and throat wash samples. Where possible,
DNA from ten million PBMC was examined from each patient
and DNA from more than six million PBMC was examined for
normal healthy donors. Whereas 50% of healthy seropositive
donors gave a positive result, no EBV DNA was detected in
the XLA patient PBMC or that of a seronegative donor. Sim-
ilarly, throat washing supernatant and cell pellet samples which
gave 80% positivity for healthy seropositive donors were uni-
formly negative for the XLA patients. Thus, our results show
conclusively that none of the six XLA patients examined is
persistently infected with EBV, whereas 15 of 16 (94%) of the
normal seropositive donors had evidence of EBV infection in
at least one of the assays used.
Between 5 and 10% of the adult population in the United
Kingdom remain apparently uninfected by EBV for life with
no immunological evidence of past or persistent infection (re-
viewed in reference 9). However, B cells from these individuals
can be infected with EBV in vitro, and it is therefore assumed
that they have escaped infection with the virus. It is possible
TABLE 6. HLA types of XLA patients and healthy donors and
HLA-restricted EBV epitopes and EBV antigens represented
Patient or
donora HLA type EBV epitope
EBV antigen
(reference)
XLA1 B8 FLRGRAYGL EBNA-3A (8)
NHD19
RAKFKQLL BZLF-1 (4)
XLA2 B44 KEHVIQNAF EBNA-3C (21)
XLA3
XLA5 EENLLDFVRF EBNA-3C (7)
XLA6
NHD15,b
NHD18
VEITPYKPTW (used
experimentally as a
peptide mix)
EBNA-3B (22)
XLA4 B7 RPPIFIRRL EBNA-3A (18)
NHD16b
NHD17
a XLA, XLA patient; NHD, normal healthy donor.
b Seronegative.
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that the six XLA patients examined here all fall into this
category because their susceptibility to opportunistic bacterial
infections has perhaps led to a sheltered lifestyle which has
protected them from infection. In fact, these individuals all
lead normal lives, attending school, pursuing careers, and
forming relationships. Moreover, as EBV is largely an asymp-
tomatic infection, except in the case of IM, there is no way of
knowingly avoiding those individuals who are shedding infec-
tious virus. In addition, serum samples from a small number of
parents and siblings of the XLA patients were screened for
antibodies to EBV. All parents and siblings tested were sero-
positive for EBV, indicating that some XLA patients could at
least have been exposed to EBV from close family members.
XLA patients’ immunotherapy contains antibodies to EBV
antigens which could reach epithelial surfaces via serous se-
cretions and protect them from primary EBV infection. How-
ever, studies on healthy EBV-seropositive individuals have
concluded that salivary antibody (IgG and IgA) responses are
unlikely to confer immunity to EBV (58). Furthermore, the
XLA patients’ intravenous immunoglobulin preparations con-
tain only trace quantities of IgA, and we found no detectable
IgG antibody to VCA in patients’ saliva. Similarly, as four of
the patients received only intramuscular immunotherapy (re-
sulting in low serum IgG levels) until the ages of 11, 12, 23, and
39 (XLA patients 4, 3, 2, and 5, respectively [Table 1]), there
was a considerable window of opportunity within which EBV
infection could have occurred, prior to the onset of potentially
protective intravenous immunotherapy.
To investigate the potentially protective role of systemic
IgG, we screened patients for HHV-6. This virus has many
parallels with EBV in that it is a ubiquitous (5, 39) herpesvirus,
exhibiting lymphotropism (26, 27) with salivary transmission
(10, 40), although we recognize that HHV-6 infection typically
occurs earlier in life than EBV (5, 9, 39). We found HHV-6
DNA at the same frequency (P 5 1) in patient and healthy
donor PBMC DNA. Thus, the results obtained from the
HHV-6 screening show that XLA patients can be infected with
a lymphotropic herpesvirus. In addition, based on the seroepi-
demiological profile of EBV taken from the general popula-
tion (reviewed in reference 9), and accounting for the ages of
these six XLA patients (Table 1), the likelihood of them all
randomly being EBV negative is 3.44 3 104:1.
FIG. 2. Bulk CTL reactivation results. Specific lysis of PHA blast target cells by EBV-specific CTLs from XLA patients and healthy donors is shown. (A)
Experiments using epitopes VEITPYKPTW (EBNA-3B) and KEHVIQNAF/EENLLDFVRF (EBNA-3C) for patients 2, 3, and 5 and NHD18 (HLA B44). (B)
Experiments using epitopes RAKFKQLL (BZLF-1) and FLRGRAYGL (EBNA-3A) for XLA1 and NHD19 (HLA B8). Specific lysis of target cells was calculated as
follows: (mean 51Cr release target cells 2 mean spontaneous release)/(mean maximum release 2 mean spontaneous release) 3 100.
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The lack of persistent EBV infection in XLA patients sug-
gested to us that either their lack of B cells renders them
uninfectible with the virus or that they had undergone primary
infection in the oropharyngeal epithelium but, because of the
absence of B cells, no lifelong persistence had been estab-
lished. To distinguish between these two possibilities, we used
the most sensitive techniques available to examine their T-cell
memory to EBV epitopes known to be presented by the par-
ticular HLA types of the patients. If the XLA patients had at
any time experienced a primary infection in the oropharyngeal
epithelium, CTLs should have been generated, although if
healthy epithelial cells are infected in vivo, the viral gene ex-
pression is as yet unclear. We assume that the full range of
both latent and lytic antigens would be expressed during pro-
ductive infection, as representatives of both sets of genes have
been shown to be coexpressed on OHL (49) including the
EBNA-2 protein which is a powerful transactivator of the other
latent viral genes (reviewed in reference 46). The experiments
were limited by the known epitopes available for recognition
by the HLA types of the patients, but the broadest range
possible were tested for memory CTL responses. However,
despite the patients having peripheral blood T-cell counts
within the normal range and by screening against lytic and
latent antigens when possible, we found no evidence of a mem-
ory CTL response to EBV from patient or healthy seronegative
donor samples, whereas all seropositive donors tested gave
strong CTL responses. That functional T cells were present in
the samples was confirmed by the fact that PHA blasts were
produced from all but one patient (where insufficient cells were
available), indicating that normal lymphoproliferative re-
sponses to stimulation with a T-cell mitogen were intact. Our
results suggest that the XLA patients are in fact uninfectible by
EBV due to their lack of mature B lymphocytes and therefore
that B cells and not epithelial cells are required for primary
infection with EBV. However, the possibility that a prior in-
fection of epithelial cells leading to a CTL response that has
since waned and is now undetectable cannot be entirely ruled
out by our findings.
Despite this, we believe that our findings support the data
presented by other groups (2, 19, 33–35, 53) and suggest that
the life cycle of EBV and its ability to infect virtually the entire
population of the world are a result of infection of intra- and
extraepithelial B cells in the oropharynx.
It can also be inferred that in the absence of a detectable
latent EBV infection in these patients, the B cell must be the
only site of viral persistence. However, if our assumption that
EBV is unable to establish primary infection in these patients
is correct, then it is presumably impossible for persistent in-
fection to ensue. Therefore, an epithelial site of latency, how-
ever unlikely, cannot be entirely ruled out in healthy individ-
uals by our study.
FIG. 3. LDA results. The proportions of wells at each of the original cell concentrations shown to contain EBV-specific CTL by chromium release assay are shown.
Specific lysis of target cells was calculated for each well: (mean 51Cr release of target cells 2 mean spontaneous release)/(mean maximum release 2 mean spontaneous
release) 3 100. Wells were considered to contain EBV-specific CTLs under the following criteria: (i) specific lysis was greater than 10%; (ii) specific lysis was at least
10% greater than that shown in the corresponding untreated target well; and (iii) specific lysis was always greater than 3 standard deviations above the mean
spontaneous release from the peptide-treated target cells.
FIG. 4. Detection of HHV-6 DNA in PBMC of XLA patients and healthy
donors. Products obtained from HHV-6 PCR performed on DNA extracted
from PBMC were analyzed by Southern blotting and hybridization. (A) Two of
five healthy donors are positive for HHV-6 by PCR. Lane 1, PCR mix control
containing water instead of template DNA; lane 2, reaction using 1 mg of DNA
from HHV-6 negative cell line B96-8; lanes 3 to 9, reactions each using 1 mg of
PBMC DNA from NHD7; lanes 10 to 15, reactions each using 1 mg of PBMC
DNA from NHD8; lane 16, reaction using 10 ml of supernatant from the T-cell
line J-jhan infected with HHV-6. (B) Three of six XLA patients are positive for
HHV-6 by PCR. Lanes 1 and 2, PCR mix controls containing water instead of
template DNA; lane 3, reaction using 1 mg of DNA from HHV-6-negative cell
line B95-8; lanes 4 to 10, reactions using 1 mg of PBMC DNA from XLA1; lanes
11 to 13, reactions using 1 mg of PBMC DNA from XLA2; lanes 14 to 20,
reactions using 1 mg of PBMC DNA from XLA3; lane 21, reaction using 10 ml
of supernatant from the T-cell line J-jhan infected with HHV-6.
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